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TEDD (Tissue Engineering for Drug Development and 
Substance Testing) is an education, R&D and networking platform 
promoting the application of 3D organotypic technologies, with the 
core goal of replacing animal experimentation for therapy devel-
opment. Based in Switzerland, TEDD is one of its kind in Europe 
focused on 3D for 3Rs. The community is composed of interna-
tional members from academia, clinics, industry and non-profits. 
Training of members is achieved through regular events at the 
national and international level, including workshops, symposia, 
company visits, scientific reviews and by providing the platform to 
generate research consortia, projects and grant applications.
General Information
The network TEDD is embedded at the Zurich University of 
Applied Sciences (ZHAW) and is therefore actively involved in re-
search and education. TEDD’s ambition is a contribution towards 
implementation of state-of-the-art and new human cell-based in 
vitro organotypic methods into routine use leading to a significant 
reduction of animal experiments in research and industry. As a 
result, we contribute to a paradigm shift, initiated and supported 
by the biomedical industry, research and government, and be-
lieve that alternative methods will help to strongly reduce animal 
experiments in the future. 3D cell culture models are becoming 
widely accepted and recognized. Current research showed that hu-
man organotypic models significantly improved cell-based drug 
screening and addressed safety and efficacy of substances more 
efficient than animal models or 2D cell cultures. However, despite 
the considerable advancement of organotypic technologies and 
partial adaptation in industry, the full potential is not yet reached. 
Further efforts are required to boost the development progress. It 
is important that the companies start adapting and implementing 
organotypic model systems into their drug development process-
es. Furthermore, a joint action will help harmonizing and stand-
ardizing 3D models according to assay, scalability and usability 
enabling direct comparison and assessing their translational value.
The Competence Centre TEDD actively contributes to these 
efforts by creating a collaborative innovation platform dedicated 
to evaluating and validating 3D cell culture technologies and or-
gan-like tissue models for therapy development. 
TEDD was founded in 2010 by the section ‘Tissue Engineering’ 
at the ZHAW and the company InSphero AG, a leading Swiss sup-
plier of organotypic 3D microtissues for drug testing and disease 
modelling. TEDD is embedded and financially supported by the 
research consortium biotechnet Switzerland. Until the end of 2019, 
TEDD was part of the National Thematic Network (NTN) Swiss 
Biotech. The Competence Centre is guided by experienced aca-
demic and industrial professionals with a steering committee and an 
international advisory board. TEDD is also a physical research cen-
tre based at the ZHAW within the Centre of Cell Biology and Tissue 
Engineering. We work with pharma, biotech, food and cosmetic 
companies on the development of robust and cost-effective solu-
tions to test their products. We have a broad portfolio of engineering 
and biofabrication technologies from spheroids to 3D bioprinting.
Summary of Achievements 2019
During the past nine years, TEDD built a reputation, know-
how and an international network to effectively promote the ad-
aptation of advanced cell-based technologies. The past 18 months 
were particularly dedicated to outreach activities and education 
about 3D for 3R. 
The milestones we accomplished up to now are:
· Serving as initiation and maturation platform for several 
successful research projects. For example, TEDD members 
developed a platform for the production and analysis of fully 
functional human 3D muscle tissues. Primary human skele-
tal muscle cells were bioprinted into a specialized well plate 
and analysed by a muscle tissue analyser device that allows 
electrical stimulation and optical read-out of the tissues when 
subjected to drug treatment. This system will be able to re-
duce the use of animal muscle tissue in research and develop-
ment (Innosuisse project No.: 27901.1). 
· Acquiring 111 TEDD members from industry, academia, 
clinics and non-profits from entire Switzerland, Europe and 
USA (30% international) and therefore being able to have a 
large impact on developments in life sciences. The majority 
of TEDD partners are from industry (60%) including young 
innovative spin-off companies, technology enablers and 
world players, such as big pharma, medtech and cosmetic 
companies. Through its activities TEDD covers and directly 
influences the entire value chain of biotech R&D relevant for 
3D tissue engineering.
· Organisation of TEDD Annual Meetings (annually since 
2012) and satellite workshops, approved by Swiss Veterinary 
Office as further education in alternatives to animal testing. 
We cover topics relevant to biofabrication and 3D cell culture 
technologies: bioprinting, stem cells, personalised medicine. 
We feature international speakers, industry exhibition and 
community exchange. Our events are known for creating an 
The 3D bioprinter training during the bioprinting workshop in 2018.
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approachable and personal atmosphere between the partici-
pants. This allows for direct interaction with the goal to create 
long-term collaborations based on trust.
· Organisation of academic workshops and industrial visits 
directly on-site of the members. We highlight member in-
stitutions, where organotypic technologies are adapted and 
implemented to make those tools available for the TEDD 
community. We visit academic centres as well as enabling 
technology providers and end users. This allows the exchange 
and direct interaction of researchers and biotech profession-
als, speeds up the technology transfer process and leads to 
customer-centric developments.
· Acting as bridge between 3R organisations and our members, 
we are an institutional member of ALTEX Edition that issues 
‘ALTEX’, ‘ALTEX Proceedings’ and the German ‘TIERethik’, 
promoting alternatives to animal experimentation and high-
lighting different aspects of the human-animal-relationship. 
We actively participate in Board Meetings shaping the jour-
nal’s future. TEDD leader Dr Markus Rimann is a Foundation 
Board Member of Animalfree Research that supports research 
projects by promoting the replacement of animal experiments. 
Dr Markus Rimann presenting TEDD to the participants of Sino-Swiss 
Workshop on Tissue Engineering in October 2019.
Activities 2020
31. January 2020 TEDD University Visit: 
Adolphe Merkle Institute, 
Fribourg, Switzerland
TEDD visited the BioNanomaterials group at Adolphe Merkle Insti-
tute (AMI). Scientists presented ongoing research projects: i) how to 
investigate the hazard of aerosolized nanomaterials such as carbon 
nanotubes with lung tissue, ii) the interaction of micro- and nano-
plastic particles with a novel intestine model, iii) the effect of diesel 
exhaust particles on skin properties using a reconstructed epidermal 
model, iv) as well as 3D bioprinting technology for the design of an 
omental model to study the dynamics of cancer cells.
12–14. May 2020 Dechema 3D Cell Culture 
2020, Freiburg, Germany
Postponed to 5.–7. May 2021
TEDD co-organises 3DCC2020 with the topic ‘From bench to appli-
cations: Get updated about 3D cell culture as predictive model systems 
and the translation from models to applications’. The conference 
highlights newest developments and translation of models to applica-
tions, success stories, trends, innovative technologies. The exhibi-
tion will showcase practical applications, products and solutions and 
further stimulate discussions between researchers, solution providers 
and users.
25. June 2020 TEDD company visit: Tecan 
Group Ltd., Männedorf, 
Switzerland
TEDD will visit Tecan, a leading global provider of automated labora-
tory instruments and solutions. Our systems and components help 
people working in clinical diagnostics, basic and translational research 
and drug discovery bring their science to life. The event will feature 
talks and company tour.
25.–27. August 2020 Biointerfaces International 
(BIC 2020), Zurich, 
Switzerland.
Postponed to  
17.–19. August 2021
TEDD co-organises the translational debate session during the confer-
ence entitled: “Progress in cell-based in vitro assays for drug devel-
opment, substance toxicity testing, and regenerative medicine – sup-
porting 3R initiatives”. The debate brings together all the important 
stakeholders from industry, science, society and politics.
8. September 2020 TEDD University Visit: 
University of Applied Sciences 
and Arts Northwestern 
Switzerland (FHNW) Muttenz, 
Switzerland
FHNW conducts research along the entire healthcare value creation 
chain. The spectrum ranges from the development of medical products 
and drugs, technologies and production processes through to their 
production and market launch.
21.–22. October 2020 TEDD Annual Meeting 2020, 
Wädenswil, Switzerland
TEDD Annual Meeting brings together experts from diverse fields 
with a shared interest in advanced 3D models. Join us for this meeting 
to celebrate another fruitful collaboration year with new perspectives 
ahead. At this two-day event we feature:
• 1-day Workshop for innovative start-ups and companies
• 1-day Symposium with international and national speakers
• 2-day Exhibition during Workshop and Symposium
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need to be made available in order to accelerate the implemen-
tation of alternative methods in routine industrial applications. 
Furthermore, joint efforts of academia and industry with regula-
tory agencies will enable developing guidelines for the validation 
and harmonisation of organotypic models.
In all these activities, TEDD sees its role in promoting the use 
of organotypic model systems and bringing the different stake-
holders together. 
At TEDD, we would like to establish ourselves, in addition to 
the regular activities, as a Swiss education centre for the dissem-
ination and use of organotypic methods for therapy development 
and for replacement of animal testing. The goal is to introduce 
and train members from industry and academia in using organo-
typic technologies, including the teaching of methods and latest 
innovations, but also stimulating the discussions on how to vali-
date and successfully implement them into the drug development 
pipeline. We believe it is important that academia and industry 
are becoming aware of the available organotypic methods and 
using them daily but also understanding what the prerequisites 
are in developing novel organotypic model systems for a given 
application.
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Previous TEDD leader and ZHAW Centre’s head Prof Michael 
Raghunath is Executive Board member of the national Swiss 
3R Competence Centre (3RCC). 3RCC promotes the 3Rs prin-
ciple in Switzerland and facilitates its implementation in life 
sciences, focusing on research, education and communication. 
· Promotion of organotypic cultures as alternatives to animal 
testing among professionals and public by regular media ap-
pearance and events. We are increasingly recognised as the 
experts in the field. TEDD is regularly active in dissemination 
by giving interviews for local newspapers and taking part in 
several popular science programs in the national Swiss TV. 
We also participated in the debate about animal use in science 
in the frame of “Pint of Science”, a science festival that aims 
to communicate contemporary scientific developments to the 
public by bringing scientists to the pub and other accessible 
places.
Vision and Future
TEDD is currently a matured platform, and our ambition is 
to bring it to the next level. It is a crucial time in Switzerland 
to make a change, as the public is more and more engaged and 
aware of ethical concerns of animal testing. Furthermore, in 2020 
the Swiss public will vote for different initiatives concerning an-
imal experimentation in research and drug development. These 
votings should raise the awareness that more financial resources 
Prof Zhongze Gu describing science and activities at the Southeast 
University of China in the framework of the Sino-Swiss Workshop on 
Tissue Engineering in October 2019.
Core team during TEDD Annual Meeting 2019: from the right – Prof 
Christian Hinderling, Dr Katarzyna Kopanska, Dr Markus Rimann, Prof 
Ursula Graf-Hausner and Dr Markus Ehrat. 
